CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

The Trump administration is pushing for reduced prices on weight-loss drugs like Wegovy and Zepbound, citing stark pricing ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Another was a looming late-stage clinical trial of a closely watched pipeline drug that's loaded with potential. For a ...

A new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Among the growth products, Trulicity generated ... an increase of 3.5% for the industry. Image Source: Zacks Investment Research Sales of Mounjaro and Zepbound were below expectations in the ...

Eli Lilly and Company LLY reported first-quarter 2025 adjusted earnings per share (“EPS”) of $3.34, which missed the Zacks Consensus Estimate of $3.52 per share. Earnings rose 29% year over year.

President Donald Trump's second term in office has been challenging for investors, at least so far. Trump imposed sweeping ...